Bridgebio Pharma Inc Revenue Growth Rates (BBIO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bridgebio Pharma Inc   (NASDAQ: BBIO)
 

BBIO's Revenue Growth by Quarter and Year

Bridgebio Pharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BBIO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 243.68
1st Quarter March 194.52
FY 438.20

BBIOs Annual Revenue
Bridgebio Pharma Inc 's Revenue in the fiscal year 2025 $ 502.08 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2024 $ 221.90 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2023 $ 9.30 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2022 $ 77.65 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2021 $ 69.72 millions




BBIO Revenue second quarter 2026 Y/Y Growth Comment
Bridgebio Pharma Inc reported Revenue surge of 120.38% year on year in the second quarter 2026, to $ 243.68 millions, this is lower than Bridgebio Pharma Inc 's recent average Revenue surge of 1593.07%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Revenue growth. While Bridgebio Pharma Inc ' s Revenue doubling of 120.38% ranks overall at the positon no. 220 in the second quarter 2026.


BBIO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 2522.11 % 236 % -6.42 %
3rd Quarter September - 4321.25 % -33.25 % 1102.94 %
2nd Quarter June 120.38 % 4995.39 % 32.32 % -97.78 %
1st Quarter March 66.78 % -44.76 % 11436.61 % 8.28 %
FY   - 126.26 % 2283.46 % -

Financial Statements
Bridgebio Pharma Inc 's second quarter 2026 Revenue $ 243.68 millions BBIO's Income Statement
Bridgebio Pharma Inc 's second quarter 2025 Revenue $ 110.57 millions Quarterly BBIO's Income Statement


BBIO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 27.74 % 115.38 % -57.21 %
3rd Quarter September - 9.16 % 25.81 % 149.39 %
2nd Quarter June 25.27 % -5.2 % -98.97 % -10.38 %
1st Quarter March 26.16 % 1883.5 % 11964 % -2.14 %
FY (Year on Year)   - 126.26 % 2283.46 % -


Back to BBIO Growth rate Comparisons >> Back to BBIO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #62
Overall #220

Revenue Y/Y Growth Statistics
High Average Low
11461.88 % 1593.07 % -99.12 %
(Jun 30 2024)   (Jun 30 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #62
Overall #220
Revenue Y/Y Growth Statistics
High Average Low
11461.88 % 1593.07 % -99.12 %
(Jun 30 2024)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bridgebio Pharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11998.57 % 1223.44 % -100 %
(Mar 31 2024)  


BBIO's II. Quarter Q/Q Revenue Comment
Bridgebio Pharma Inc achieved in the II. Quarter 2026 below company average Revenue jump of 25.27% quarter on quarter, to $ 243.68 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the -5.2% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Bridgebio Pharma Inc 's Revenue growth quarter on quarter, overall rank is 423.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #94
Overall #423
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #94
Overall #423
Revenue Q/Q Growth Statistics
High Average Low
11998.57 % 1223.44 % -100 %
(Mar 31 2024)  


BBIO's II. Quarter Q/Q Revenue Comment
Bridgebio Pharma Inc achieved in the II. Quarter 2026 below company average Revenue jump of 25.27% quarter on quarter, to $ 243.68 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -5.2% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Bridgebio Pharma Inc 's Revenue growth quarter on quarter, overall rank is 423.


Bridgebio Pharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 713.07 $ 579.96 $ 502.08 $ 353.78 $ 235.81
Y / Y Revenue Growth (TTM) 202.39 % 355.17 % 126.26 % 62.46 % 7.62 %
Year on Year Revenue Growth Overall Ranking # 1648 # 2857 # 8 # 4 # 5
Seqeuential Revenue Change (TTM) 22.95 % 15.51 % 41.92 % 50.03 % 85.07 %
Seq. Revenue Growth (TTM) Overall Ranking # 194 # 2861 # 2038 # 2251 # 1869


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Bridgebio Pharma Inc 's cumulative twelve months Revenue were $ 713 millions, company would post below average annual Revenue growth of 85.07% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Bridgebio Pharma Inc 's Revenue growth from the 194.52% growth in Mar 31 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1648, from total ranking in previous quarter at 2857.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 264
Overall # 1648

Revenue TTM Y/Y Growth Statistics
High Average Low
3761.22 %
 529.39 %
-93.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 52
S&P 500 # 194
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Bridgebio Pharma Inc 's cumulative twelve months Revenue were $ 713 millions, company would post below average annual Revenue growth of -93.74% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Bridgebio Pharma Inc 's Revenue growth from the 194.52% growth in Mar 31 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1648, from total ranking in previous quarter at 2857.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 264
Overall # 1648

Revenue TTM Y/Y Growth Statistics
High Average Low
3761.22 %
529.39 %
-93.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 52
S&P 500 # 194




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BBIO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions


About Bridgebio Pharma Inc Revenue Growth Rates (BBIO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bridgebio Pharma Inc (CIK 1743881).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001743881-26-000027
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bridgebio Pharma Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.